bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplemental Methods from RhoB Determines Tumor Aggressiveness in a Murine EGFRL858R-Induced Adenocarcinoma Model and Is a Potential Prognostic Biomarker for Lepidic Lung Cancer
Authors: Calvayrac Olivier , Pradines Anne , Raymond-Letron Isabelle , Rouquette Isabelle , Bousquet Emilie , Lauwers-Cances Valérie , Filleron Thomas , Cadranel Jacques , Beau-Faller Michèle , Casanova Anne , Milia Julie , Favre Gilles , Mazières Julien
Published: April 2023

Supplemental Methods. This file contains additional methodology (Tumor/lung ratio quantification, Tumor size measurement and grading, CD34 staining and quantification, lung tissue processing for protein extraction for Western Blotting and PAS diastase staining)
Supplementary Table 2 from Monoclonal Antibodies Targeting LecLex-Related Glycans with Potent Antitumor Activity
Authors: Chua Jia Xin , Vankemmelbeke Mireille , McIntosh Richard S. , Clarke Philip A. , Moss Robert , Parsons Tina , Spendlove Ian , Zaitoun Abid M. , Madhusudan Srinivasan , Durrant Lindy G.
Published: April 2023

Supplementary Table 2. containing IHC scoring of FG88.2 and FG88.7 binding to AMS bio normal human tissue
Supplementary Materials and Methods from Monoclonal Antibodies Targeting LecLex-Related Glycans with Potent Antitumor Activity
Authors: Chua Jia Xin , Vankemmelbeke Mireille , McIntosh Richard S. , Clarke Philip A. , Moss Robert , Parsons Tina , Spendlove Ian , Zaitoun Abid M. , Madhusudan Srinivasan , Durrant Lindy G.
Published: April 2023

Supplementary Materials and Methods relating to Flow Cytometry, Lewis ELISA, Affinity Analysis and DNA Fragmentation
supplementary figure 5 from Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs)
Authors: Alfaro Carlos , Teijeira Alvaro , Oñate Carmen , Pérez Guiomar , Sanmamed Miguel F. , Andueza Maria Pilar , Alignani Diego , Labiano Sara , Azpilikueta Arantza , Rodriguez-Paulete Alfonso , Garasa Saray , Fusco Juan P. , Aznar Angela , Inogés Susana , De Pizzol Maria , Allegretti Marcello , Medina-Echeverz Jose , Berraondo Pedro , Perez-Gracia Jose L. , Melero Ignacio
Published: April 2023

Supplementary figure 5. Suppressive activity of MoMDSC on autologous purified CD4 and CD8 T cells. Experiments as in figure 5 but in this case immunomagnetically purified T cells by negative selection were CFSE-labeled co-cultured as indicated. T lymphocytes were differentially analyzed for proliferation in FACS-gated CD4 or CD8 T cell subsets. Representative histograms of one experiment out of two performed are represented.
Supplementary Figure 1 from Monoclonal Antibodies Targeting LecLex-Related Glycans with Potent Antitumor Activity
Authors: Chua Jia Xin , Vankemmelbeke Mireille , McIntosh Richard S. , Clarke Philip A. , Moss Robert , Parsons Tina , Spendlove Ian , Zaitoun Abid M. , Madhusudan Srinivasan , Durrant Lindy G.
Published: April 2023

Supplementary Figure 1. containing Lewis glycan competition analysis, Lewis a ELISA (titration for EC50) and HCT-15 cell surface binding (titration for Kd)
Supplementary Figure and Table Legends. from Doxorubicin Synergizes with 34.5ENVE to Enhance Antitumor Efficacy against Metastatic Ovarian Cancer
Authors: Bolyard Chelsea , Yoo Ji Young , Wang Pin-Yi , Saini Uksha , Rath Kellie S. , Cripe Timothy P. , Zhang Jianying , Selvendiran Karuppaiyah , Kaur Balveen
Published: April 2023

Supplementary Figure and Table Legends. Supplementary legends for figures and tables characterizing patient ascites samples.
Supplemental Figure 3 from Keratin 19, a Cancer Stem Cell Marker in Human Hepatocellular Carcinoma
Authors: Kawai Takayuki , Yasuchika Kentaro , Ishii Takamichi , Katayama Hokahiro , Yoshitoshi Elena Yukie , Ogiso Satoshi , Kita Sadahiko , Yasuda Katsutaro , Fukumitsu Ken , Mizumoto Masaki , Hatano Etsuro , Uemoto Shinji
Published: April 2023

Supplemental Figure 3. Cancer stem cell properties of K19+ PLC/PRF/5 and Hep3B cells in vivo
Supplemental Figure 5 from Lysyl Oxidase (LOX) Transcriptionally Regulates SNAI2 Expression and TIMP4 Secretion in Human Cancers
Authors: Boufraqech Myriem , Zhang Lisa , Nilubol Naris , Sadowski Samira M. , Kotian Shweta , Quezado Martha , Kebebew Electron
Published: April 2023

Angiogenesis-related proteins and VEGF secretion in cancer cells
Supplementary Tables S1-S3 and Supplementary Figures S1-S6 from Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL
Authors: Stubbs Matthew C. , Kim Wonil , Bariteau Megan , Davis Tina , Vempati Sridhar , Minehart Janna , Witkin Matthew , Qi Jun , Krivtsov Andrei V. , Bradner James E. , Kung Andrew L. , Armstrong Scott A.
Published: April 2023

Supplementary Tables S1-S3 and Supplementary Figures S1-S6. Table S1 - EC50 values for B-cell malignancies treated with HDAC inhibitors of varying isoform selectivity Table S2 - EC50 values for B-ALL cell line treated with a panel of HDAC inhibitors Table S3 - statistics for cell growth assay in Figure 3 Figure S1 - In vitro survival and PD for B-ALL cells treated with LAQ824 Figure S2 - Western analyses of B-ALL cells treated with MS275 Figure S3 - Western blots, cell growth and cell cycle analysis for B-ALL cells transduced with HDAC1,2, or 3 specific shRNA Figure S4 - Western analyses, cell growth and survival of B-ALL cell treated with Merck60 Figure S5 - Survival and western blots for B-ALL cells treated with HDACi with an apoptosis inhibitor. Figure S6 - Western blots to show DNA damage caused by HDACi or doxorubicin in Merck60 insensitive multiple myeloma cell lines.
Supplementary Table S1-S3 Legends and Supplementary Figure S1-S6 Legends from Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL
Authors: Stubbs Matthew C. , Kim Wonil , Bariteau Megan , Davis Tina , Vempati Sridhar , Minehart Janna , Witkin Matthew , Qi Jun , Krivtsov Andrei V. , Bradner James E. , Kung Andrew L. , Armstrong Scott A.
Published: April 2023

Supplementary Table S1-S3 Legends and Supplementary Figure S1-S6 Legends. Legends for supplementary tables S1-S3 and supplementary figures S1-S6 which support data in the manuscript, but could not be included due to space constraints.
Supplemental Figure 2 from Lysyl Oxidase (LOX) Transcriptionally Regulates SNAI2 Expression and TIMP4 Secretion in Human Cancers
Authors: Boufraqech Myriem , Zhang Lisa , Nilubol Naris , Sadowski Samira M. , Kotian Shweta , Quezado Martha , Kebebew Electron
Published: April 2023

Regulation of SNAI2 by LOX in MCF-7 and BCPAP cells
Supplementary Figures from Dual Targeting of Tissue Factor and CD105 for Preclinical PET Imaging of Pancreatic Cancer
Authors: Luo Haiming , England Christopher G. , Shi Sixiang , Graves Stephen A. , Hernandez Reinier , Liu Bai , Theuer Charles P. , Wong Hing C. , Nickles Robert J. , Cai Weibo
Published: April 2023

Supplementary Figure 1. Purification of heterodimer after click chemistry conjugation of ALT-836-Fab and TRC105-Fab Supplementary Figure 2. MALDI-TOF mass spectra of ALT-836-Fab: [M+H]+ = 47266.0, TRC105-Fab: [M+H]+ = 47454.7, and heterodimer: exact [M+H]+ = 103504.0. Supplementary Figure 3. Flow cytometry analysis in BXPC-3 after 1 h incubation of FITC-Fab conjugates for the comparison of their in vitro targeting Supplementary Figure 4. Radiolabeling efficiency at different copper: immunoconjugate ratios were used to determine the number of NOTA per antibody fragment molecule Supplementary Figure 5. PET imaging and biodistribution of 64CuCl2 in BXPC-3 tumor-bearing mice. Supplementary Figure 6. PET imaging and quantitative ROI analysis of 64Cu-NOTA-heterodimer with TF and CD105 dual-blocking in BXPC-3 tumor-bearing mice. Supplementary Figure 7. Coronal images and transverse PET/CT images of normal nude mice at 3, 15, 24 and 30 h following injection of 64Cu-NOTA-heterodimer Supplementary Figure 8. PET ROI-derived quantification of 64Cu-NOTA-heterodimer uptake in the tumor, normal pancreas, blood pool, liver, kidney and muscle at 3 h, 15 h, 24 h and 30 h p.i. of the tracer
Supplementary Methods from Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity
Authors: Jacobsen Helle J. , Poulsen Thomas T. , Dahlman Anna , Kjær Ida , Koefoed Klaus , Sen Jette W. , Weilguny Dietmar , Bjerregaard Bolette , Andersen Christina R. , Horak Ivan D. , Pedersen Mikkel W. , Kragh Michael , Lantto Johan
Published: April 2023

Supplementary Methods. Description of methods used for assessment of synergy, immunohistochemistry, cell death, cell cycle arrest, ADCC and CDC.
Supplemental Figures (revised) from MACC1 Induces Tumor Progression in Transgenic Mice and Colorectal Cancer Patients via Increased Pluripotency Markers Nanog and Oct4
Authors: Lemos Clara , Hardt Markus S. , Juneja Manisha , Voss Cynthia , Förster Susann , Jerchow Boris , Haider Wolfram , Bläker Hendrik , Stein Ulrike
Published: April 2023

Supplementary Figure 1. Generation of transgenic mice with IEC-specific overexpression of MACC1. Supplementary Figure 2. Characterization of the vil-MACC1 transgenic mice Supplementary Figure 3. MACC1 transgene expression in the vil-MACC1/ApcMin mice. Supplementary Figure 4. Characterization of the vil-MACC1/ApcMin mice. Supplementary Figure 5. Pathway analysis of the Affymetrix microarray.
Supplemental Figure Legend S1 from Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation
Authors: Hasegawa Masanori , Sinha Raj Kumar , Kumar Manoj , Alam Maroof , Yin Li , Raina Deepak , Kharbanda Akriti , Panchamoorthy Govind , Gupta Dikshi , Singh Harpal , Kharbanda Surender , Kufe Donald
Published: April 2023

Supplemental Figure Legend S1
Supplementary Figure Legends from Sorafenib Inhibition of Mcl-1 Accelerates ATRA-Induced Apoptosis in Differentiation-Responsive AML Cells
Authors: Wang Rui , Xia Lijuan , Gabrilove Janice , Waxman Samuel , Jing Yongkui
Published: April 2023

Supplementary Figure Legends
Supplementary Figure 3 from Sorafenib Inhibition of Mcl-1 Accelerates ATRA-Induced Apoptosis in Differentiation-Responsive AML Cells
Authors: Wang Rui , Xia Lijuan , Gabrilove Janice , Waxman Samuel , Jing Yongkui
Published: April 2023

Differentiation induction of ATRA in three AML cell lines
Supplementary Figures S3-S4 from Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non–Small Cell Lung Cancer
Authors: Song Ahnah , Kim Tae Min , Kim Dong-Wan , Kim Soyeon , Keam Bhumsuk , Lee Se-Hoon , Heo Dae Seog
Published: April 2023

Supplementary Figures S3-S4. Supplementary Figure S3: ROS1 and its downstream signals in HCC78CR1-3 cells after crizotinib exposure. Supplementary Figure S4: p-ROS1 and total ROS1 expression of ROS1-mutant Ba/F3 cells after exposure to foretinib or TAE-684.
Supplementary Figure 1 from Sorafenib Inhibition of Mcl-1 Accelerates ATRA-Induced Apoptosis in Differentiation-Responsive AML Cells
Authors: Wang Rui , Xia Lijuan , Gabrilove Janice , Waxman Samuel , Jing Yongkui
Published: April 2023

Apoptosis and differentiation induction of ATRA in Bcl-2 and Mcl-1 overexpressed HL-60 cells
Supplementary Information from Elevated Coexpression of KITENIN and the ErbB4 CYT-2 Isoform Promotes the Transition from Colon Adenoma to Carcinoma Following APC loss
Authors: Bae Jeong A , Kho Dhong Hyo , Sun Eun Gene , Ko Yoo-Seung , Yoon Somy , Lee Kyung Hwa , Ahn Kyu Youn , Lee Jae Hyuk , Joo Young Eun , Chung Ik Joo , Lee Sug Hyung , Kim Hangun , Kim Kyung Keun
Published: April 2023

Supplementary Figure legends; Supplementary Materials and Methods: Detailed and expanded methods on cell lines, in-vitro assays, in-vivo tumor model, histology, and tumor specimens for all data presented.
Supplementary Fig S1 from miR-154* and miR-379 in the DLK1-DIO3 MicroRNA Mega-Cluster Regulate Epithelial to Mesenchymal Transition and Bone Metastasis of Prostate Cancer
Authors: Gururajan Murali , Josson Sajni , Chu Gina Chia-Yi , Lu Chia-Lun , Lu Yi-Tsung , Haga Christopher L. , Zhau Haiyen E. , Liu Chunyan , Lichterman Jake , Duan Peng , Posadas Edwin M. , Chung Leland W.K.
Published: April 2023

Supplementary Fig S1. miR-154* staining of human tissues was performed as described in the Methods section. Values are represented as intensity counts/cell, (n=1, duplicate samples from the same patient tumor tissues were stained).
Supplementary Figure 5 from Elevated Coexpression of KITENIN and the ErbB4 CYT-2 Isoform Promotes the Transition from Colon Adenoma to Carcinoma Following APC loss
Authors: Bae Jeong A , Kho Dhong Hyo , Sun Eun Gene , Ko Yoo-Seung , Yoon Somy , Lee Kyung Hwa , Ahn Kyu Youn , Lee Jae Hyuk , Joo Young Eun , Chung Ik Joo , Lee Sug Hyung , Kim Hangun , Kim Kyung Keun
Published: April 2023

Immunohistochemical analyses of nontumor intestinal tissues from the APCmin/+ mouse and the compound KIT-TG/APCmin/+ mouse.
Supplementary Figure 3 from Elevated Coexpression of KITENIN and the ErbB4 CYT-2 Isoform Promotes the Transition from Colon Adenoma to Carcinoma Following APC loss
Authors: Bae Jeong A , Kho Dhong Hyo , Sun Eun Gene , Ko Yoo-Seung , Yoon Somy , Lee Kyung Hwa , Ahn Kyu Youn , Lee Jae Hyuk , Joo Young Eun , Chung Ik Joo , Lee Sug Hyung , Kim Hangun , Kim Kyung Keun
Published: April 2023

Effects of elevated KITENIN on cell proliferation and anoikis of intestinal epithelial cells.
Supplemental Figure 2 from Reproducible, Quantitative, and Flexible Molecular Subtyping of Clinical DLBCL Samples Using the NanoString nCounter System
Authors: Veldman-Jones Margaret H. , Lai Zhongwu , Wappett Mark , Harbron Chris G. , Barrett J. Carl , Harrington Elizabeth A. , Thress Kenneth S.
Published: April 2023

Supplemental Figure 2. COO designations across cell lines
Supplementary Figure S1. from Development of a Model System to Evaluate Local Recurrence in Osteosarcoma and Assessment of the Effects of Bone Morphogenetic Protein-2
Authors: Geller David S. , Singh Michael Y. , Zhang Wendong , Gill Jonathan , Roth Michael E. , Kim Mimi Y. , Xie Xianhong , Singh Christopher K. , Dorfman Howard D. , Villanueva-Siles Esperanza , Park Amy , Piperdi Sajida , Gorlick Richard
Published: April 2023

Supplementary Figure S1. ROC curves for OS17 recurrence vs. average bone margin length.
Figure S2 from Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer
Authors: Giraldo Nicolas A. , Becht Etienne , Pagès Franck , Skliris Georgios , Verkarre Virginie , Vano Yann , Mejean Arnaud , Saint-Aubert Nicolas , Lacroix Laetitia , Natario Ivo , Lupo Audrey , Alifano Marco , Damotte Diane , Cazes Aurelie , Triebel Frederic , Freeman Gordon J. , Dieu-Nosjean Marie-Caroline , Oudard Stephane , Fridman Wolf H. , Sautès-Fridman Catherine
Published: April 2023

Figure S2. CD8+ and PD1+ cell density and Furhman Grade in primary ccRCC
Supplemental Table 2 from Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor–Redirected T Cells Against Multiple Myeloma
Authors: Wang Xiuli , Walter Miriam , Urak Ryan , Weng Lihong , Huynh Christian , Lim Laura , Wong ChingLam W. , Chang Wen-Chung , Thomas Sandra H. , Sanchez James F. , Yang Lu , Brown Christine E. , Pichiorri Flavia , Htut Myo , Krishnan Amrita Y. , Forman Stephen J.
Published: April 2023

Up-regulated genes
SUPPLE data ofFASN-GIST-CCR-R1, including Methods-S1-S9, Legends-S1-S12, and Tables-S1-S2 from Overexpressed Fatty Acid Synthase in Gastrointestinal Stromal Tumors: Targeting a Progression-Associated Metabolic Driver Enhances the Antitumor Effect of Imatinib
Authors: Li Chien-Feng , Fang Fu-Min , Chen Yen-Yang , Liu Ting-Ting , Chan Ti-Chun , Yu Shih-Chen , Chen Li-Tzong , Huang Hsuan-Ying
Published: April 2023

SUPPLE data ofFASN-GIST-CCR-R1, including Methods-S1-S9, Legends-S1-S12, and Tables-S1-S2
Figure S6 from Downregulation of SAFB Sustains the NF-κB Pathway by Targeting TAK1 during the Progression of Colorectal Cancer
Authors: Jiao Hong-Li , Ye Ya-Ping , Yang Run-Wei , Sun Hui-Ying , Wang Shu-Yang , Wang Yong-Xia , Xiao Zhi-Yuan , He Liu-Qing , Cai Juan-Juan , Wei Wen-Ting , Chen Yan-Ru , Gu Chun-Cai , Cai Yue-Long , Hu Yun-Teng , Lai Qiu-Hua , Qiu Jun-Feng , Liang Li , Cao Guang-Wen , Liao Wen-Ting , Ding Yan-Qing
Published: April 2023

Figure S6 shows that expression of SAFB in CRC tissue was negatively correlated with that of TAK1 and NF-κB-related genes.
Table S2 from Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non–Small Cell Lung Cancer
Authors: Cooper Wendy A. , Russell Prudence A. , Cherian Maya , Duhig Edwina E. , Godbolt David , Jessup Peter J. , Khoo Christine , Leslie Connull , Mahar Annabelle , Moffat David F. , Sivasubramaniam Vanathi , Faure Celine , Reznichenko Alena , Grattan Amanda , Fox Stephen B.
Published: April 2023

Table S2 shows agreement with gold standard depending on PD-L1 tumor proportion score per gold standard. Agreements for trained and untrained participating pathologists were compared.
Supplementary Table S6 from Global Protease Activity Profiling Provides Differential Diagnosis of Pancreatic Cysts
Authors: Ivry Sam L. , Sharib Jeremy M. , Dominguez Dana A. , Roy Nilotpal , Hatcher Stacy E. , Yip-Schneider Michele T. , Schmidt C. Max , Brand Randall E. , Park Walter G. , Hebrok Matthias , Kim Grace E. , O'Donoghue Anthony J. , Kirkwood Kimberly S. , Craik Charles S.
Published: April 2023

Protease activity data in relation to revised Sendai criteria for 71 mucinous cysts.
Supplementary figures from Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition
Authors: Pereira Carolina , Gimenez-Xavier Pol , Pros Eva , Pajares Maria J. , Moro Massimo , Gomez Antonio , Navarro Alejandro , Condom Enric , Moran Sebastian , Gomez-Lopez Gonzalo , Graña Osvaldo , Rubio-Camarillo Miriam , Martinez-Martí Alex , Yokota Jun , Carretero Julian , Galbis Jose M. , Nadal Ernest , Pisano David , Sozzi Gabriella , Felip Enriqueta , Montuenga Luis M. , Roz Luca , Villanueva Alberto , Sanchez-Cespedes Montse
Published: April 2023

Supplementary Figure 1, 2,3 4,5
Supplementary Table S5 from Global Protease Activity Profiling Provides Differential Diagnosis of Pancreatic Cysts
Authors: Ivry Sam L. , Sharib Jeremy M. , Dominguez Dana A. , Roy Nilotpal , Hatcher Stacy E. , Yip-Schneider Michele T. , Schmidt C. Max , Brand Randall E. , Park Walter G. , Hebrok Matthias , Kim Grace E. , O'Donoghue Anthony J. , Kirkwood Kimberly S. , Craik Charles S.
Published: April 2023

Diagnostic performance of individual and combination markers in cyst fluid samples.
Supplementary Figure 1 from Signal Transduction and Activator of Transcription-3 (STAT3) in Patients with Colorectal Cancer: Associations with the Phenotypic Features of the Tumor and Host
Authors: Park James H. , van Wyk Hester , McMillan Donald C. , Quinn Jean , Clark Jennifer , Roxburgh Campbell S.D. , Horgan Paul G. , Edwards Joanne
Published: April 2023

The relationship between tumour cell STAT3 expression and cancer-specific survival of patients undergoing elective, potentially curative resection of stage I-III colorectal cancer (Kaplan-Meier log-rank analysis): (a) Stage T1-2 (P<0.001), (b) Stage T3-4 (P=0.192), (c) Node negative (P=0.516), and (d) Node positive (P=0.001).
Supplemental Figure 1 from Disruption of Autophagic Degradation with ROC-325 Antagonizes Renal Cell Carcinoma Pathogenesis
Authors: Carew Jennifer S. , Espitia Claudia M. , Zhao William , Han Yingchun , Visconte Valeria , Phillips James , Nawrocki Steffan T.
Published: April 2023

Supplemental Figure 1. H NMR of ROC-325 in D2O
Supplementary Figure legends from BQ323636.1, a Novel Splice Variant to NCOR2, as a Predictor for Tamoxifen-Resistant Breast Cancer
Authors: Gong Chun , Man Ellen P.S. , Tsoi Ho , Lee Terence K.W. , Lee Paul , Ma Sai-Ting , Wong Lai-San , Luk Mai-Yee , Rakha Emad A. , Green Andrew R. , Ellis Ian O. , Lam Eric W.-F. , Cheung Kwok-Leung , Khoo Ui-Soon
Published: April 2023

Supplementary figure legends
Table S6 from The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)
Authors: Aisner Dara L. , Sholl Lynette M. , Berry Lynne D. , Rossi Michael R. , Chen Heidi , Fujimoto Junya , Moreira Andre L. , Ramalingam Suresh S. , Villaruz Liza C. , Otterson Gregory A. , Haura Eric , Politi Katerina , Glisson Bonnie , Cetnar Jeremy , Garon Edward B. , Schiller Joan , Waqar Saiama N. , Sequist Lecia V. , Brahmer Julie , Shyr Yu , Kugler Kelly , Wistuba Ignacio I. , Johnson Bruce E. , Minna John D. , Kris Mark G. , Bunn Paul A. , Kwiatkowski David J.
Published: April 2023

Supplemental Table 6. TP53 mutations seen in subjects in LCMC2, and categorization as disruptive or nondisruptive.
LCMC2-Suppl_Fig_Legends from The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)
Authors: Aisner Dara L. , Sholl Lynette M. , Berry Lynne D. , Rossi Michael R. , Chen Heidi , Fujimoto Junya , Moreira Andre L. , Ramalingam Suresh S. , Villaruz Liza C. , Otterson Gregory A. , Haura Eric , Politi Katerina , Glisson Bonnie , Cetnar Jeremy , Garon Edward B. , Schiller Joan , Waqar Saiama N. , Sequist Lecia V. , Brahmer Julie , Shyr Yu , Kugler Kelly , Wistuba Ignacio I. , Johnson Bruce E. , Minna John D. , Kris Mark G. , Bunn Paul A. , Kwiatkowski David J.
Published: April 2023

Supplemental Figure Legends
Figure S6 from BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti–PD-1 Antibody
Authors: Sanlorenzo Martina , Vujic Igor , Floris Arianna , Novelli Mauro , Gammaitoni Loretta , Giraudo Lidia , Macagno Marco , Leuci Valeria , Rotolo Ramona , Donini Chiara , Basiricò Marco , Quaglino Pietro , Fierro Maria Teresa , Giordano Silvia , Sibilia Maria , Carnevale-Schianca Fabrizio , Aglietta Massimo , Sangiolo Dario
Published: April 2023

Fig. S6: In-vitro anti-PD1 antibody only marginally improved BRAF/MEKi efficacy. Cell viability of melanoma cells treated with BRAF/MEKi (dabrafenib+trametinib [1mcM+5nM]) in BRAFV600 mutant cell lines and trametinib [5nM] in the NRASQ61 mutant cell line) in combination with anti-PD1 antibody [100mcg/ml] or isotype control antibody [100mcg/ml] for 72h in BRAFV600 mutant cell lines and for 120h in the NRASQ61 mutant cell line. Averages and standard deviations. No significant differences were found.
Figure S5 from BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti–PD-1 Antibody
Authors: Sanlorenzo Martina , Vujic Igor , Floris Arianna , Novelli Mauro , Gammaitoni Loretta , Giraudo Lidia , Macagno Marco , Leuci Valeria , Rotolo Ramona , Donini Chiara , Basiricò Marco , Quaglino Pietro , Fierro Maria Teresa , Giordano Silvia , Sibilia Maria , Carnevale-Schianca Fabrizio , Aglietta Massimo , Sangiolo Dario
Published: April 2023

Fig. S5: Anti-PD1 antibody alone did not affect melanoma cell viability. Cell viability of melanoma cells treated with 100mcg/ml and 400mcg/ml of anti-PD1 antibody for 72 hours. Averages and standard deviations. No significant differences were found.
Figure S3 from BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Anti–PD-1 Antibody
Authors: Sanlorenzo Martina , Vujic Igor , Floris Arianna , Novelli Mauro , Gammaitoni Loretta , Giraudo Lidia , Macagno Marco , Leuci Valeria , Rotolo Ramona , Donini Chiara , Basiricò Marco , Quaglino Pietro , Fierro Maria Teresa , Giordano Silvia , Sibilia Maria , Carnevale-Schianca Fabrizio , Aglietta Massimo , Sangiolo Dario
Published: April 2023

Fig. S3. In NRASQ61 mutant cells MEKi alone leads to highest levels of PD1+ melanoma cells. Representative flow cytometry plots of a NRASQ61 mutant melanoma cell line (SKMEL2) treated with dabrafenib [1mcM], trametinib [5nM], the combination of dabrafenib + trametinib [1mcM+5nM], and fotemustine [50mcg/ml] for 96 hours. DAPI staining was used to identify viable cells. PD1, PDL1, PDL2 plots were performed considering only viable cells.
Supplementary methods from The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome
Authors: Ricciardelli Carmela , Bianco-Miotto Tina , Jindal Shalini , Butler Lisa M. , Leung Samuel , McNeil Catriona M. , O'Toole Sandra A. , Ebrahimie Esmaeil , Millar Ewan K.A. , Sakko Andrew J. , Ruiz Alexandra I. , Vowler Sarah L. , Huntsman David G. , Birrell Stephen N. , Sutherland Robert L. , Palmieri Carlo , Hickey Theresa E. , Tilley Wayne D.
Published: April 2023

Supplementary Methods
Supplementary Table S1 from PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer
Authors: Yang Yinhui , Bai Yang , He Yundong , Zhao Yu , Chen Jiaxiang , Ma Linlin , Pan Yunqian , Hinten Michael , Zhang Jun , Karnes R. Jeffrey , Kohli Manish , Westendorf Jennifer J. , Li Benyi , Zhu Runzhi , Huang Haojie , Xu Wanhai
Published: April 2023

Primers used for genotyping and RT-qPCR studies.
Supplementary Figure S4 from PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer
Authors: Yang Yinhui , Bai Yang , He Yundong , Zhao Yu , Chen Jiaxiang , Ma Linlin , Pan Yunqian , Hinten Michael , Zhang Jun , Karnes R. Jeffrey , Kohli Manish , Westendorf Jennifer J. , Li Benyi , Zhu Runzhi , Huang Haojie , Xu Wanhai
Published: April 2023

Panel A shows genotyping of wild-type, Ptenpc-/-, Runx2+/- and Ptenpc-/-;Runx2+/- mice. Panel B shows effectiveness of Pten deletion in wild-type and Ptenpc-/- mouse prostates with IHC. Panel C and D show Runx2 deletion in the prostate of Ptenpc-/- and Ptenpc-/-;Runx2+/- mice detected by real-time PCR and IHC, respectively.
Supplementary Figure S1 from PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer
Authors: Yang Yinhui , Bai Yang , He Yundong , Zhao Yu , Chen Jiaxiang , Ma Linlin , Pan Yunqian , Hinten Michael , Zhang Jun , Karnes R. Jeffrey , Kohli Manish , Westendorf Jennifer J. , Li Benyi , Zhu Runzhi , Huang Haojie , Xu Wanhai
Published: April 2023

In panel A, RUNX2 knockdown in C4-2B cells completely abolished NVP-BEZ235-induced inhibition of expression of CYP11A1 and CYP17A1 mRNA. In panel B, ectopic expression of FOXO1-A3 failed to induce overt changes in RUNX2 expression at both mRNA and protein levels in C4-2B cells. In panel C-E, overexpression of OCN reversed RUNX2 knockdown-induced downregulation of the expression of CYP11A1 and CYP17A1 genes and RUNX2 knockdown-induced decrease in intratumoral testosterone levels.
Supplemental Text from The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma
Authors: Schinke Carolina , Qu Pingping , Mehdi Syed J. , Hoering Antje , Epstein Joshua , Johnson Sarah K. , van Rhee Frits , Zangari Maurizio , Thanendrarajan Sharmilan , Barlogie Bart , Davies Faith E. , Yaccoby Shmuel , Morgan Gareth J.
Published: April 2023

Supplemental tables and figures
Supplementary Table 9 from Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer
Authors: Xu Chang , Nikolova Olga , Basom Ryan S. , Mitchell Ryan M. , Shaw Reid , Moser Russell D. , Park Heuijoon , Gurley Kay E. , Kao Michael C. , Green Carlos L. , Schaub Franz X. , Diaz Robert L. , Swan Hallie A. , Jang In S. , Guinney Justin , Gadi Vijayakrishna K. , Margolin Adam A. , Grandori Carla , Kemp Christopher J. , Méndez Eduardo
Published: April 2023

Supplementary Table 9
Supplementary Table 6-7 from Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer
Authors: Xu Chang , Nikolova Olga , Basom Ryan S. , Mitchell Ryan M. , Shaw Reid , Moser Russell D. , Park Heuijoon , Gurley Kay E. , Kao Michael C. , Green Carlos L. , Schaub Franz X. , Diaz Robert L. , Swan Hallie A. , Jang In S. , Guinney Justin , Gadi Vijayakrishna K. , Margolin Adam A. , Grandori Carla , Kemp Christopher J. , Méndez Eduardo
Published: April 2023

Supplementary Table 6, 7
Supplementary Table 5 from Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer
Authors: Xu Chang , Nikolova Olga , Basom Ryan S. , Mitchell Ryan M. , Shaw Reid , Moser Russell D. , Park Heuijoon , Gurley Kay E. , Kao Michael C. , Green Carlos L. , Schaub Franz X. , Diaz Robert L. , Swan Hallie A. , Jang In S. , Guinney Justin , Gadi Vijayakrishna K. , Margolin Adam A. , Grandori Carla , Kemp Christopher J. , Méndez Eduardo
Published: April 2023

Supplementary Table 5
Suppl. Fig. 4 from Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes
Authors: Mohme Malte , Schliffke Simon , Maire Cecile L. , Rünger Alessandra , Glau Laura , Mende Klaus C. , Matschke Jakob , Gehbauer Christina , Akyüz Nuray , Zapf Svenja , Holz Mareike , Schaper Miriam , Martens Tobias , Schmidt Nils O. , Peine Sven , Westphal Manfred , Binder Mascha , Tolosa Eva , Lamszus Katrin
Published: April 2023

Supplemental data of next-generation T-cell receptor sequencing.
Suppl. Fig. 3 from Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes
Authors: Mohme Malte , Schliffke Simon , Maire Cecile L. , Rünger Alessandra , Glau Laura , Mende Klaus C. , Matschke Jakob , Gehbauer Christina , Akyüz Nuray , Zapf Svenja , Holz Mareike , Schaper Miriam , Martens Tobias , Schmidt Nils O. , Peine Sven , Westphal Manfred , Binder Mascha , Tolosa Eva , Lamszus Katrin
Published: April 2023

Additional cytokines determined by multiplex flow-cytometry after PHA stimulation of PBL.
Suppl. Fig. 2 from Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes
Authors: Mohme Malte , Schliffke Simon , Maire Cecile L. , Rünger Alessandra , Glau Laura , Mende Klaus C. , Matschke Jakob , Gehbauer Christina , Akyüz Nuray , Zapf Svenja , Holz Mareike , Schaper Miriam , Martens Tobias , Schmidt Nils O. , Peine Sven , Westphal Manfred , Binder Mascha , Tolosa Eva , Lamszus Katrin
Published: April 2023

Flow-cytometry gating strategy for T-cell memory/activation and ectoenzymatic exhaustion markers.
Supplementary Figures from Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer
Authors: Xu Chang , Nikolova Olga , Basom Ryan S. , Mitchell Ryan M. , Shaw Reid , Moser Russell D. , Park Heuijoon , Gurley Kay E. , Kao Michael C. , Green Carlos L. , Schaub Franz X. , Diaz Robert L. , Swan Hallie A. , Jang In S. , Guinney Justin , Gadi Vijayakrishna K. , Margolin Adam A. , Grandori Carla , Kemp Christopher J. , Méndez Eduardo
Published: April 2023

Supplementary Figures
Supplementary Figure 1 from Liver Microvascular Injury and Thrombocytopenia of Antibody–Calicheamicin Conjugates in Cynomolgus Monkeys—Mechanism and Monitoring
Authors: Guffroy Magali , Falahatpisheh Hadi , Biddle Kathleen , Kreeger John , Obert Leslie , Walters Karen , Goldstein Richard , Boucher Germaine , Coskran Timothy , Reagan William , Sullivan Danielle , Huang Chunli , Sokolowski Sharon , Giovanelli Richard , Gerber Hans-Peter , Finkelstein Martin , Khan Nasir
Published: April 2023

PF-0259 did not induce platelet sequestration in kidney or lung. Monkeys were necropsied 48 hours after a single intravenous administration of vehicle or PF-0259 at 6 mg/m2. CD41 IHC for platelets was performed on kidney and lung samples from vehicle control (A and C, respectively) and PF-0259-dosed (B and D, respectively) monkeys. Contrary to what was observed in the liver, there was no increase in CD41 immunostaining and therefore no evidence of platelet sequestration in the kidney and lung vasculature following PF-0259 administration. Scale bar = 60 Âµm.
Figure S1, Table S2 from Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study
Authors: Norquist Barbara M. , Brady Mark F. , Harrell Maria I. , Walsh Tom , Lee Ming K. , Gulsuner Suleyman , Bernards Sarah S. , Casadei Silvia , Burger Robert A. , Tewari Krishnansu S. , Backes Floor , Mannel Robert S. , Glaser Gretchen , Bailey Cheryl , Rubin Stephen , Soper John , Lankes Heather A. , Ramirez Nilsa C. , King Mary Claire , Birrer Michael J. , Swisher Elizabeth M.
Published: April 2023

Survival by mutation type, and mutation data by the source of sequenced DNA
Suppl. Figure 10 from Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma
Authors: Dettling Steffen , Stamova Slava , Warta Rolf , Schnölzer Martina , Rapp Carmen , Rathinasamy Anchana , Reuss David , Pocha Kolja , Roesch Saskia , Jungk Christine , Warnken Uwe , Eckstein Volker , Grabe Niels , Schramm Christoph , Weigand Markus A. , von Deimling Andreas , Unterberg Andreas , Beckhove Philipp , Herold-Mende Christel
Published: April 2023

(A) Applied gating strategy (one representative patient, NCH645) for the expression analysis of tumor-associated antigens in IDHmut lower-grade glioma and secondary glioblastoma GSCs, analyzed by flow cytometry in regard to an adequate isotype control. (B) Fluorescence intensity measurements for the isotype control and the antigen expressing (positive) GSC population, showing counts in percentage [%] over the mean PE-intensity.(C) Gating strategy, including the markers pacific orange (PO), CD3, and CD8, used for quantification of antigen-specific peripheral cytotoxic CD3+CD8+ T-cells by flow cytometry and (D) antigen-loaded pMHC I-tetramers (PE-conjugated) and the respective positive (Influenza M1) as well as negative control HLA-A*02-tetramers. GSCs: glioma stem-like cells, HIV: human immunodeficiency virus, HLA: human leukocyte antigen, MHC: major histocompatibility complex, PE: Phycoerythrin, pos: positive, US: unstained.
Supplemental Figure 4 from A Novel Breast Cancer Index for Prediction of Distant Recurrence in HR+ Early-Stage Breast Cancer with One to Three Positive Nodes
Authors: Zhang Yi , Schroeder Brock E. , Jerevall Piiha-Lotta , Ly Amy , Nolan Hannah , Schnabel Catherine A. , Sgroi Dennis C.
Published: April 2023

Supplemental Figure 4 shows the prognostic performance of BCIN+ for overall 15-year (A,C) and late post-5-year (B,D) distant recurrence in HER2-negative patients with 1-3 positive nodes.
Figure S6 from Monoclonal Antibodies Directed against Cadherin RGD Exhibit Therapeutic Activity against Melanoma and Colorectal Cancer Metastasis
Authors: Bartolomé Rubén A. , Aizpurua Carmen , Jaén Marta , Torres Sofía , Calviño Eva , Imbaud Juan I. , Casal J. Ignacio
Published: April 2023

RGD mAbs blocking effects require the presence of α2 integrin
Tolerable toxicity after repeated intravaginal administration of IL-7-Fc. from Intravaginal Administration of Fc-Fused IL7 Suppresses the Cervicovaginal Tumor by Recruiting HPV DNA Vaccine-Induced CD8 T Cells
Authors: Choi Young Woo , Kang Moon Cheol , Seo Yong Bok , Namkoong Hong , Park Yunji , Choi Dong-Hoon , Suh You Suk , Lee Seung-Woo , Sung Young Chul , Jin Hyun-Tak
Published: April 2023

Supplementary Table 1. Tolerable toxicity after repeated intravaginal administration of IL-7-Fc. Information of detailed materials and methods, and supplementary figure legends are contained.
Route-dependency of IL-7-Fc administration on recruitment of T cells in cervicovaginal tissue from Intravaginal Administration of Fc-Fused IL7 Suppresses the Cervicovaginal Tumor by Recruiting HPV DNA Vaccine-Induced CD8 T Cells
Authors: Choi Young Woo , Kang Moon Cheol , Seo Yong Bok , Namkoong Hong , Park Yunji , Choi Dong-Hoon , Suh You Suk , Lee Seung-Woo , Sung Young Chul , Jin Hyun-Tak
Published: April 2023

Supplementary Figure 6. Route-dependency of IL-7-Fc administration on recruitment of T cells in cervicovaginal tissue
Comparison of Fc-fragment and IL-7-Fc on accumulation of T cells in cervicovaginal tissue from Intravaginal Administration of Fc-Fused IL7 Suppresses the Cervicovaginal Tumor by Recruiting HPV DNA Vaccine-Induced CD8 T Cells
Authors: Choi Young Woo , Kang Moon Cheol , Seo Yong Bok , Namkoong Hong , Park Yunji , Choi Dong-Hoon , Suh You Suk , Lee Seung-Woo , Sung Young Chul , Jin Hyun-Tak
Published: April 2023

Supplementary Figure 4. Comparison of Fc-fragment and IL-7-Fc on accumulation of T cells in cervicovaginal tissue
Abrogation of T cell accumulation after IL-7Rα blocking from Intravaginal Administration of Fc-Fused IL7 Suppresses the Cervicovaginal Tumor by Recruiting HPV DNA Vaccine-Induced CD8 T Cells
Authors: Choi Young Woo , Kang Moon Cheol , Seo Yong Bok , Namkoong Hong , Park Yunji , Choi Dong-Hoon , Suh You Suk , Lee Seung-Woo , Sung Young Chul , Jin Hyun-Tak
Published: April 2023

Supplementary Figure 5. Abrogation of T cell accumulation after IL-7Rα blocking
Supplementary Table S7 from Deep Sequencing of Urinary RNAs for Bladder Cancer Molecular Diagnostics
Authors: Sin Mandy L.Y. , Mach Kathleen E. , Sinha Rahul , Wu Fan , Trivedi Dharati R. , Altobelli Emanuela , Jensen Kristin C. , Sahoo Debashis , Lu Ying , Liao Joseph C.
Published: April 2023

Table summarizing the univariate logistic analysis for predicting bladder cancer of 11 candidate genes (8 cancer and 3 reference genes) that were evaluated in the training cohort (n=102).
Supplementary Table S1 from Deep Sequencing of Urinary RNAs for Bladder Cancer Molecular Diagnostics
Authors: Sin Mandy L.Y. , Mach Kathleen E. , Sinha Rahul , Wu Fan , Trivedi Dharati R. , Altobelli Emanuela , Jensen Kristin C. , Sahoo Debashis , Lu Ying , Liao Joseph C.
Published: April 2023

Full list of differentially expressed genes identified in comparison of the 13 bladder cancer urine samples to 8 control urine samples based on urinary RNA-seq data in the urinary biomarker discovery.
Supplementary Figure S1 from Deep Sequencing of Urinary RNAs for Bladder Cancer Molecular Diagnostics
Authors: Sin Mandy L.Y. , Mach Kathleen E. , Sinha Rahul , Wu Fan , Trivedi Dharati R. , Altobelli Emanuela , Jensen Kristin C. , Sahoo Debashis , Lu Ying , Liao Joseph C.
Published: April 2023

Gene expression of the candidate reference genes for model construction in 29 urine samples using qPCR. The Ct values of the 5 reference genes, the standard derivation and grand mean Ct values of all samples over all 5 genes were plotted.
table s1 from Evaluation of Tumor-Derived Exosomal miRNA as Potential Diagnostic Biomarkers for Early-Stage Non–Small Cell Lung Cancer Using Next-Generation Sequencing
Authors: Jin Xiance , Chen Yanfan , Chen Hanbin , Fei Shaoran , Chen Didi , Cai Xiaona , Liu Linger , Lin Baochai , Su Huafang , Zhao Lihao , Su Meng , Pan Huanle , Shen Lanxiao , Xie Deyao , Xie Congying
Published: April 2023

The raw miRNA-seq data
Figure S6 from Demethylation Therapy as a Targeted Treatment for Human Papillomavirus–Associated Head and Neck Cancer
Authors: Biktasova Asel , Hajek Michael , Sewell Andrew , Gary Cyril , Bellinger Gary , Deshpande Hari A. , Bhatia Aarti , Burtness Barbara , Judson Benjamin , Mehra Saral , Yarbrough Wendell G. , Issaeva Natalia
Published: April 2023

A. % line-1 methylation after 5-aza treatment in HPV+ (1-5) and HPV- tumors from the window clinical trial. B. % Line-1 methylation in HPV+ UMSCC47 cells before and after 5-aza treatment
Figure S5 from Demethylation Therapy as a Targeted Treatment for Human Papillomavirus–Associated Head and Neck Cancer
Authors: Biktasova Asel , Hajek Michael , Sewell Andrew , Gary Cyril , Bellinger Gary , Deshpande Hari A. , Bhatia Aarti , Burtness Barbara , Judson Benjamin , Mehra Saral , Yarbrough Wendell G. , Issaeva Natalia
Published: April 2023

A. Zymogram gel showing activity of proteases that use casein as a substrate in growth medium from UMSCC47 cells treated or untreated with 5-aza. B. Expression of MMPs 2 and 9 before and after 5-aza treatment in UMSCC47 cells as determined in the Illumina array
Figure S2 from Demethylation Therapy as a Targeted Treatment for Human Papillomavirus–Associated Head and Neck Cancer
Authors: Biktasova Asel , Hajek Michael , Sewell Andrew , Gary Cyril , Bellinger Gary , Deshpande Hari A. , Bhatia Aarti , Burtness Barbara , Judson Benjamin , Mehra Saral , Yarbrough Wendell G. , Issaeva Natalia
Published: April 2023

DNMT1, p53, phospho-p53 Ser15 and gamma H2AX levels in UMSCC47 cells treated with 5-aza or zeocin for 48 hours. Actin was used as a loading control
Figure S1 from Demethylation Therapy as a Targeted Treatment for Human Papillomavirus–Associated Head and Neck Cancer
Authors: Biktasova Asel , Hajek Michael , Sewell Andrew , Gary Cyril , Bellinger Gary , Deshpande Hari A. , Bhatia Aarti , Burtness Barbara , Judson Benjamin , Mehra Saral , Yarbrough Wendell G. , Issaeva Natalia
Published: April 2023

A. Cytokeratin levels in HPV+ and HPV- cells used in the study; human osteosarcoma cells U2OS were used as a negative control. B. TP53 mRNA levels in UMSCC47 cells expressing control, or two different p53 shRNAs. C. Cytokeratin levels in tumors from a window clinical trial
Pub fees email yes from A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors
Authors: Geoerger Birgit , Bourdeaut Franck , DuBois Steven G. , Fischer Matthias , Geller James I. , Gottardo Nicholas G. , Marabelle Aurélien , Pearson Andrew D.J. , Modak Shakeel , Cash Thomas , Robinson Giles W. , Motta Marlyane , Matano Alessandro , Bhansali Suraj G. , Dobson Jason R. , Parasuraman Sudha , Chi Susan N.
Published: April 2023

Pub fees email yes
Supplemental Information from PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Authors: Jiao Shiping , Xia Weiya , Yamaguchi Hirohito , Wei Yongkun , Chen Mei-Kuang , Hsu Jung-Mao , Hsu Jennifer L. , Yu Wen-Hsuan , Du Yi , Lee Heng-Huan , Li Chia-Wei , Chou Chao-Kai , Lim Seung-Oe , Chang Shih-Shin , Litton Jennifer , Arun Banu , Hortobagyi Gabriel N. , Hung Mien-Chie
Published: April 2023

Supplementary Figure S1. PARPi upregulates PD-L1 in a dose-dependent manner in MD-MB-231 cells. Supplementary Figure S2. Downregulation of BRCA1 or BRCA2 has no effect on PARPi-induced PD-L1 upregulation. Supplementary Figure S3. PARPi inactivates GSK3Î². Supplementary Figure S4. PARPi blocks cell proliferation of MDA-MB-231 cells but not activated PBMCs. Supplementary Figure S5. Toxicity assessment of treatment on BALB/c mice.
Supplementary figures from Preclinical Development of a Nontoxic Oral Formulation of Monoethanolamine, a Lipid Precursor, for Prostate Cancer Treatment
Authors: Saxena Roopali , Yang Chunhua , Rao Mukkavilli , Turaga Ravi Chakra , Garlapati Chakravarthy , Gundala Sushma Reddy , Myers Kimberly , Ghareeb Ahmed , Bhattarai Shristi , Kamalinia Golnaz , Bristi Sangina , Su Dan , Gadda Giovanni , Rida Padmashree C.G. , Cantuaria Guilherme H. , Aneja Ritu
Published: April 2023

This file contains supplementary figures.
Supplementary Figures from The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care
Authors: Paíno Teresa , Garcia-Gomez Antonio , González-Méndez Lorena , San-Segundo Laura , Hernández-García Susana , López-Iglesias Ana-Alicia , Algarín Esperanza M. , Martín-Sánchez Montserrat , Corbacho David , Ortiz-de-Solorzano Carlos , Corchete Luis A. , Gutiérrez Norma C. , Maetos María-Victoria , Garayoa Mercedes , Ocio Enrique M.
Published: April 2023

-Supplementary Figure 1. Evaluation of apoptosis and cell cycle in MM cell lines after PIM447 treatment. -Supplementary Figure 2. PIM447 very strongly synergizes with different antimyeloma agents in the RPMI-8226 cell line. -Supplementary Figure 3. Effect of PIM447 on PIM kinase-related targets in RPMI-8226, NCI-H929 and OPM-2 cells. -Supplementary Figure 4. Correlation analysis between PIM kinase-related targets and sensitivity to PIM447. -Supplementary Figure 5. Oral administration of PIM447 does not significantly affect body weight in a mouse model of disseminated MM.
Supplementary Table S2 from Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in RETM918T Tumors
Authors: Mancikova Veronika , Montero-Conde Cristina , Perales-Paton Javier , Fernandez Agustin , Santacana María , Jodkowska Karolina , Inglada-Pérez Lucia , Castelblanco Esmeralda , Borrego Salud , Encinas Mario , Matias-Guiu Xavier , Fraga Mario , Robledo Mercedes
Published: April 2023

Additional probes lying in putative miRNA promoters identified using the PROmiRNA method (27).
SUPPLEMENTS: Antihypoxic Effects of Myo-Inositol Trispyrophosphate on Vasculature and Therapy of Colorectal Liver Metastasis from Antihypoxic Potentiation of Standard Therapy for Experimental Colorectal Liver Metastasis through Myo-Inositol Trispyrophosphate
Authors: Limani Perparim , Linecker Michael , Kachaylo Ekaterina , Tschuor Christoph , Kron Philipp , Schlegel Andrea , Ungethuem Udo , Jang Jae Hwi , Georgiopoulou Stavroula , Nicolau Claude , Lehn Jean-Marie , Graf Rolf , Humar Bostjan , Clavien Pierre-Alain
Published: April 2023

Supplementary Methods and Figure Legends
Supplementary Table S1 from Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in RETM918T Tumors
Authors: Mancikova Veronika , Montero-Conde Cristina , Perales-Paton Javier , Fernandez Agustin , Santacana María , Jodkowska Karolina , Inglada-Pérez Lucia , Castelblanco Esmeralda , Borrego Salud , Encinas Mario , Matias-Guiu Xavier , Fraga Mario , Robledo Mercedes
Published: April 2023

Primers used in the mutation analysis of the samples. Examples of identified mutations are also shown.
Supplementary Figure S2 from Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in RETM918T Tumors
Authors: Mancikova Veronika , Montero-Conde Cristina , Perales-Paton Javier , Fernandez Agustin , Santacana María , Jodkowska Karolina , Inglada-Pérez Lucia , Castelblanco Esmeralda , Borrego Salud , Encinas Mario , Matias-Guiu Xavier , Fraga Mario , Robledo Mercedes
Published: April 2023

A principal component analysis using 14,346 probes did not reveal any apparent batch effect between the two arrays.
Supplementary Figure S5 from Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia
Authors: Amin Nisar A. , Balasubramanian Sriram , Saiya-Cork Kamlai , Shedden Kerby , Hu Nan , Malek Sami N.
Published: April 2023

Effects of TP53 disruption on BCR signaling in the PGA1 CLL lymphoblastoid cell line:
Supplemental Figure Legends from TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor–Positive Breast Cancer
Authors: Jeselsohn Rinath , Barry William T. , Migliaccio Ilenia , Biagioni Chiara , Zhao Jin , De Tribolet-Hardy Jonas , Guarducci Cristina , Bonechi Martina , Laing Naomi , Winer Eric P. , Brown Myles , Leo Angelo Di , Malorni Luca
Published: April 2023

Supplemental Figure Legends
Supplemental Figure 1 from TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor–Positive Breast Cancer
Authors: Jeselsohn Rinath , Barry William T. , Migliaccio Ilenia , Biagioni Chiara , Zhao Jin , De Tribolet-Hardy Jonas , Guarducci Cristina , Bonechi Martina , Laing Naomi , Winer Eric P. , Brown Myles , Leo Angelo Di , Malorni Luca
Published: April 2023

QC analysis
Supplementary Figure legends from CTLA-4 Limits Anti-CD20–Mediated Tumor Regression
Authors: Ren Zhenhua , Guo Jingya , Liao Jing , Luan Yan , Liu Zhida , Sun Zhichen , Liu Xiaojuan , Liang Yong , Peng Hua , Fu Yang-Xin
Published: April 2023

Supplementary Figure legends